SpyGlass Pharma, Inc. SGP
33.32 USD -1.65 (-4.72%)
At closeNov 12, 2026, 4:26 PM EST
33.32 0.00 0.00%
After hours · Nov 12, 4:26 PM ET
33.15 Day range 35.68
17.06 52-week range 39.92
- YTD
- +26.21%
- 1 year
- +26.21%
News
benzinga.com HC Wainwright & Co. Maintains Buy on SpyGlass Pharma, Raises Price Target to $43 HC Wainwright & Co. analyst Yi Chen maintains SpyGlass Pharma (NASDAQ:SGP) with a Buy and raises the price target from $37 to $43.
benzinga.com SpyGlass Pharma Q3 EPS $(0.73) Misses $(0.63) Estimate SpyGlass Pharma (NASDAQ:SGP) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.63) by 15.87 percent. This is a 83.89 percent increase over losses of…
globenewswire.com SpyGlass Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Updates IRVINE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today reported recent business…
globenewswire.com SpyGlass Pharma to Participate in Upcoming Investor Conferences IRVINE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today announced that members of the…
benzinga.com HC Wainwright & Co. Reiterates Buy on SpyGlass Pharma, Maintains $37 Price Target HC Wainwright & Co. analyst Yi Chen reiterates SpyGlass Pharma (NASDAQ:SGP) with a Buy and maintains $37 price target.
benzinga.com SpyGlass Pharma Announces Trial Results From Bimatoprost Drug Pad-IOL System In Participants With Mild-To-Moderate Open Angle Glaucoma Reduces Mean IOP By 37% Across All Three Dose Cohorts; 86% Participants Remained Off All Topical IOP-Lowering Drops SpyGlass Pharma, Inc. (Nasdaq: SGP) ("SpyGlass Pharma" or "Company"), a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye
globenewswire.com SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL System Groundbreaking 4-year safety and efficacy results: 37% reduction in mean intraocular pressure (IOP) across all dose groups 86% of patients remained off all topical IOP-lowering drops 90% of patients…
businesswire.com EdgeConneX Enters Australia in Partnership with Stockland, with Hyperscale Data Center Campuses Planned in Sydney and Melbourne SYDNEY--(BUSINESS WIRE)--EdgeConneX®, a pioneer in global Build-to-Suit and Build-to-Density digital infrastructure solutions, today announced its entry into the Australian market through a 50-50…
benzinga.com HC Wainwright & Co. Reiterates Buy on SpyGlass Pharma, Maintains $37 Price Target HC Wainwright & Co. analyst Yi Chen reiterates SpyGlass Pharma (NASDAQ:SGP) with a Buy and maintains $37 price target.
benzinga.com SpyGlass Pharma Acquires Advanced Vision Science For ~$13M In Cash SpyGlass Pharma acquires 100% of the outstanding shares of AVS, a subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), the existing manufacturer of SpyGlass Pharma’s intraocular lens (IOL)Secures…
globenewswire.com SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability IRVINE, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”) announced today the acquisition of all the outstanding shares of common stock of…
seekingalpha.com SpyGlass Pharma, Inc. (SGP) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript SpyGlass Pharma, Inc. (SGP) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
globenewswire.com SpyGlass Pharma to Participate in Upcoming Investor Conferences IRVINE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today announced that members of the…
benzinga.com This Aehr Test Systems Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday (CORRECTED) Wall Street analysts changed ratings for top names. Visit our analyst ratings page for details. SGP initiated with Outperform, $39 PT.
247wallst.com Here Are Friday’s Top Wall Street Analyst Research Calls: Cinemark, Digital Realty, Fox Corporation, Krystal Biotech, LTC Properties, Roku, Sandisk, T-Mobile US, Wayfair, and More Wall Street flipped the script Friday with a wave of surprise upgrades and downgrades hitting names like Wayfair, Roku, and Fox Corporation, while cooler inflation data reshuffled bets across stocks,…
benzinga.com Raymond James Initiates Coverage On SpyGlass Pharma with Outperform Rating, Announces Price Target of $39 Raymond James analyst Christopher Raymond initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a Outperform rating and announces Price Target of $39.
globenewswire.com SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027. Bimatoprost-Drug Ring System…
defenseworld.net Spyglass Pharma (NASDAQ:SGP) Shares Gap Up – Still a Buy? Spyglass Pharma, Inc. (NASDAQ: SGP - Get Free Report)'s stock price gapped up prior to trading on Friday. The stock had previously closed at $20.88, but opened at $21.80. Spyglass Pharma shares last…
defenseworld.net Affinity Asset Advisors LLC Buys Shares of 250,000 Spyglass Pharma, Inc. $SGP Affinity Asset Advisors LLC purchased a new position in shares of Spyglass Pharma, Inc. (NASDAQ: SGP) during the undefined quarter, according to its most recent 13F filing with the Securities and…
globenewswire.com SpyGlass Pharma Appoints Shannon Treviño as General Counsel ALISO VIEJO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma or Company), a late-stage biopharmaceutical company, today announced the appointment of…
globenewswire.com SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing ALISO VIEJO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced the appointment of Mike Pinder as…
globenewswire.com SpyGlass Pharma to Participate in Upcoming Investor Conferences ALISO VIEJO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today announced that members of the…
benzinga.com SpyGlass Says AMA CPT Editorial Panel Approves New Add-On Category III CPT Code For Attachment, Insertion Of Intraocular Lens Prosthesis-Mounted Drug-Eluting Implant SpyGlass Pharma, Inc. (NASDAQ:SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced that the American Medical Association's (AMA) CPT® (Current Procedural Terminology)…
globenewswire.com SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System ALISO VIEJO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced that the American Medical…- benzinga.com SpyGlass Pharma Q1 EPS $(0.69) Misses $(0.42) Estimate SpyGlass Pharma (NASDAQ:SGP) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.42) by 64.29 percent. This is a 82.58 percent increase over losses of…
globenewswire.com SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates ALISO VIEJO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today reported recent business…
defenseworld.net Analyzing Longevity Health (NASDAQ:XAGE) and Spyglass Pharma (NASDAQ:SGP) Spyglass Pharma (NASDAQ: SGP - Get Free Report) and Longevity Health (NASDAQ: XAGE - Get Free Report) are both small-cap manufacturing companies, but which is the superior stock? We will contrast the…- benzinga.com SpyGlass Pharma Q4 EPS $(5.72) Down From $(4.58) YoY SpyGlass Pharma (NASDAQ:SGP) reported quarterly losses of $(5.72) per share. This is a 24.89 percent decrease over losses of $(4.58) per share from the same period last year.
globenewswire.com SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update ALISO VIEJO, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today reported recent business…
defenseworld.net Comparing Spyglass Pharma (NASDAQ:SGP) & Nanovibronix (NASDAQ:FEED) Nanovibronix (NASDAQ: FEED - Get Free Report) and Spyglass Pharma (NASDAQ: SGP - Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will contrast the…
defenseworld.net Longevity Health (NASDAQ:XAGE) and Spyglass Pharma (NASDAQ:SGP) Financial Comparison Spyglass Pharma (NASDAQ: SGP - Get Free Report) and Longevity Health (NASDAQ: XAGE - Get Free Report) are both small-cap manufacturing companies, but which is the better stock? We will contrast the…
benzinga.com HC Wainwright & Co. Initiates Coverage On SpyGlass Pharma with Buy Rating, Announces Price Target of $37 HC Wainwright & Co. analyst Yi Chen initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a Buy rating and announces Price Target of $37.- benzinga.com SpyGlass Pharma Announces Positive Topline 1/2 Trial Results For BIM-IOL Intracranial Pressure Treatment 12-month results from the Phase 1/2 trial evaluating its lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), for the treatment of elevated intraocular pressure (IOP) in…
benzinga.com This MongoDB Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday Wall Street analysts changed ratings on top companies. See full list at benzinga.com/analyst-stock-ratings. MDB outlook downgraded to Neutral.- benzinga.com Citigroup Initiates Coverage On SpyGlass Pharma with Buy Rating, Announces Price Target of $42 Citigroup analyst Yigal Nochomovitz initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a Buy rating and announces Price Target of $42.
- benzinga.com Leerink Partners Initiates Coverage On SpyGlass Pharma with Outperform Rating, Announces Price Target of $42 Leerink Partners analyst Marc Goodman initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a Outperform rating and announces Price Target of $42.
- benzinga.com Jefferies Initiates Coverage On SpyGlass Pharma with Buy Rating, Announces Price Target of $62 Jefferies analyst Dennis Ding initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a Buy rating and announces Price Target of $62.
benzinga.com This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday Top Wall Street analysts changed outlook on top names. Check out analyst ratings page for all changes. AMLX, OFRM, AGMB, SGP initiated with positive outlook.- benzinga.com Stifel Initiates Coverage On SpyGlass Pharma with Buy Rating, Announces Price Target of $42 Stifel analyst Tom Stephan initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a Buy rating and announces Price Target of $42.
benzinga.com Spyglass Pharma, Inc To Start Trading Tomorrow - benzinga.com Assistant Secretary for International Finance Charles Collyns Written Testimony before the House Committee on Financial Services Subcommittee on International Monetary Policy and Trade
- benzinga.com UPDATE: ISI Group Initiates Coverage on NetApp at Buy, $48 PT
- benzinga.com Benzinga's Political Roundup
- benzinga.com Time Warner Director Buys $1 Million Worth Of Shares (TWX, SGP)
- benzinga.com The World's Largest M&A Deals in 2009 (PFE, WLA, GM, SGP, MRK)
- benzinga.com Priceline.com Added To The S&P 500, Replacing Schering-Plough
benzinga.com European Commission Approves Schering-Plough (SGP) and Centocor's Simponi Drug - benzinga.com US Court Rejects the Attempt by Schering-Plough's (SGP) to Repatriate $690M without Taxes
- benzinga.com SGP Reports Second Quarter 2009 Results VANCOUVER, BRITISH COLUMBIA--(Marketwire - Aug. 14, 2009) - NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS…